Status Epilepticus Consensus Statement 2023

Status Epilepticus and Acute Seizure Management Consensus Statement 2023

The ACVIM Consensus statement about status epilepticus (SE) was published this past summer (2023) and I felt it was applicable to all of us faced with acute seizure management. They dove right in and addressed the need for a definition of a prolonged seizure as one occurring for longer than 5 minutes. The human equivalent of our International Veterinary Epilepsy Task Force (IVETF) is the International League Against Epilepsy (ILAE). The ILAE has recently also revised their definition of SE to any seizure longer than 5 minutes as well. Previously, SE was defined as anything between 5-30 minutes. Thirty minutes was the cut off because at that point, brain damage is common. The reason for adopting the 5 minute rule was to 1) minimize the risk of systemic and brain complications associated with continuous seizure activity reaching up to 30 minutes; 2) prevent worsening of the prognosis and drug resistance associated with increasing duration of uncontrolled seizure activity and 3) limit any potentially unfavorable outcomes and adverse effects associated with the prolonged administration of multiple therapeutic interventions. 

Status Epilepticus is divided into 4 stages:
1) Impending (occurs at 5-10 minutes of seizures) - there is neurotransmitter imbalance and ion channel opening/closing. Animals are likely to be responsive to first line anticonvulsant drugs (ACD) during stage 1. 
2) Established (occurs at 10-30 minutes)- Inhibitory neurotransmitters are reduced, the receptors for the inhibitory neurotransmitters are internalized and there is upregulation of NMDR and AMPAR. Some animals may still be responsive to first line ACD, but most will be responsive to second line ACD.
3) Refractory - (occurs > 30 minutes) - There is a sustained imbalance between inhibitory and excitatory neuropeptides with BBB drug transporter upregulation. Most pets will not be responsive to first or second line ACD, but should be responsive to third line ACD. 
4) (Super)refractory - (occurs > 24 hours) - There are gene expression alterations and animals are expected to be refractory to all ACDs. 

What were considered first line ACDs? IV benzodiazepine drugs were considered the most effective and safest for in-hospital use and intranasal benzodiazepines are the preferred treatment for out-of-hospital treatment. "Although both midazolam and diazepam are potent and safe for the management of SE in dogs and cats, midazolam may be considered a more potent or safer benzodiazepine drug than diazepam." There we go!

They provided a list of the steps to follow, based on the evidence reviewed, when treating SE. I have repeated it here, but encourage you to read the entire article if you treat SE regularly as there are loads of pearls of wisdom peppered throughout the paper.

Steps to follow for SE:

• Give midazolam or diazepam IV. A benzodiazepine bolus is effective if the seizure stops < 5 minutes after administration and no relapse occurs <10 minutes

• If seizure activity is controlled with a benzodiazepine drug but recurs 10-60 minutes later is considered recurrent SE

• Recurrent SE, or those that don't respond to the first bolus of benzodiazepine, should get a second IV dose of benzodiazepine drug

• If seizures persist after two bolus, administer a 3rd dose immediately followed by a CRI. Dogs = midazolam or diazepam CRI is acceptable; Cats = diazepam should be avoided. 

• If seizures still persist, administer a 4th dose of benzodiazepine and administer a second line ACD

• Second line ACD include levetiracetam IV, followed by phenobarbital IV and lastly fosphenytoin IV. Only administer the subsequent drug if the prior failed to stop the seizures. 

Note: Levetiracetam or phenobarbital IV can be started after step 2 above if long-term maintenance is desired for either medication. They do not need to be reserved for second line use only. 

I think that is enough for today. I'll go through some more data from the study in another TidBit Tuesday. I hope you enjoy the rest of this week, have a safe, relaxing holiday and look forward to working with you soon!

IVDH Consensus Statement – Medical Management Data

In July 2022, the ACVIM Consensus Statement on the diagnosis and management of acute canine thoracolumbar intervertebral (IVD) disc extrusion was published. This is the first of two installments about this consensus statement as a TidBit Tuesday. For this one, we will discuss the expected outcomes from medical vs. surgical management and what entails medical management. Enjoy!

The recommendations by the committee were graded as being supported by high, medium and low levels of evidence. Recommendations with high level of confidence include multiple randomized controlled trials with concordant findings. The evidence strongly supports the conclusions. Medium level of confidence includes retrospective studies with concordant findings, or small placebo-controlled trials. The evidence suggest that the findings are likely to be real. Lastly, low levels of confidence include isolated or small retrospective studies or single non-controlled trials. The evidence suggests that the findings might be real.

Medical vs. Surgical IVD extrusion management

A very helpful table was presented to help guide appropriate treatment for dogs presenting with signs consistent with TL IVD extrusion. The “%” represent the % of dogs that respond favorably to medical (M) or surgical (S) treatment.

·         Pain only: M 80%, S 98.5% à lateral extrusion may lead to reduced response to medical management.

·         Non-ambulatory paraparesis: M 81%, S 93% à level of recovery was less with medical management.

·         Paraplegia with deep pain: M 60%, S 93% à medical recovery is prolonged and less complete.

·         Paraplegia loss of deep pain: M 21%, S 61%

This is based on moderate level of evidence.  The statement here is “In paraplegic deep pain negative dogs, success with medical management is largely poor with an increased frequency of progressive myelomalacia. Surgical management is recommended.” – moderate to high level evidence.

What is medical management?

“At least 4 weeks of restricted activity is recommended, putatively to promote the healing of the annulus fibrosus. This period should include confinement to a restricted area 9crate, ideally, or small room without furniture) except when performing rehabilitation exercises or outdoor toileting. There should be no off-leash walking, no jumping on or off furniture and no access to stairs during this time”. This statement was supported by low level evidence. Corticosteroids are NOT recommended (moderate level evidence). Dogs with NSAIDs had a higher quality of life score than those on corticosteroids but NO STUDIES specifically address the use (or no use) of NSAIDS. Pain management is discussed, but no recommendations were made because of the lack of studies evaluating different medication protocols. Acupuncture was noted to be good adjunctive treatment for medical management but is not a recommended substitution for surgical management. What are my typical recommendations? For an uncomplicated T3-L3 myelopathy without MRI, with a strong suspicion of IVDH, I recommend NSAIDs, muscle relaxants and most importantly, cage rest for at least 3 weeks.

I hope this was enlightening. Please reach out with questions and stay tuned for the next update on the consensus statement. I hope you have a wonderful week. I am enjoying our tiptoe into fall and hope you are too!